JSPR Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-0.668

-58.75%

-0.723

-48.7%

-0.740

-57.47%

Estimates Revision

The market is revising No Change the revenue expectations for Jasper Therapeutics, Inc. (JSPR) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -37.08%.

EPS Estimates for FY2025

Revise Downward

-4.82%

In Past 3 Month

Stock Price

Go Down

-37.08%

In Past 3 Month

6 Analyst Rating

Wall Street analysts forecast JSPR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for JSPR is 9.25 USD with a low forecast of 4.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

2 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

4.00

Averages

9.25

High

20.00

Current: 0.000

Low

4.00

Averages

9.25

High

20.00

Citizens JMP

Outperform

NULL

downgrade

$12 -> $6

2025-09-22

Reason

Citizens JMP

Price Target

$12 -> $6

2025-09-22

downgrade

Outperform

NULL

Reason

Citizens JMP lowered the firm's price target on Jasper Therapeutics to $6 from $12 and keeps an Outperform rating on the shares. Jasper Therapeutics announced early findings from its investigation into the confounding results from two cohorts in the BEACON study, and the issue now points to sites or enrolled patients, the analyst says. Jasper also announced the pricing of a $30M public offering, which will extend its runway past updated CSU data coming at year-end 2025 and into the third quarter of 2026. The bridge financing deal removes a key overhang for Jasper, Citizens says.

UBS

Buy

downgrade

$29 -> $25

2025-08-15

Reason

UBS

Price Target

$29 -> $25

2025-08-15

downgrade

Buy

Reason

UBS lowered the firm's price target on Jasper Therapeutics to $25 from $29 and keeps a Buy rating on the shares. Jasper's Q2 print was "straightforward," while the focus turns to the critical BEACON data in Q4, the analyst tells investors in a research note.

RBC Capital

Outperform -> Sector Perform

downgrade

$46 -> $5

2025-07-08

Reason

RBC Capital

Price Target

$46 -> $5

2025-07-08

downgrade

Outperform -> Sector Perform

Reason

RBC Capital downgraded Jasper Therapeutics to Sector Perform from Outperform with a price target of $5, down from $46.

Citizens JMP

Outperform

NULL

downgrade

$70 -> $12

2025-07-08

Reason

Citizens JMP

Price Target

$70 -> $12

2025-07-08

downgrade

Outperform

NULL

Reason

Citizens JMP lowered the firm's price target on Jasper Therapeutics to $12 from $70 and keeps an Outperform rating on the shares after the company disclosed updates for the Phase 1b/2a BEACON study of briquilimab for chronic spontaneous urticaria. The CSU readout fell flat due to a likely manufacturing issue and the company will try again in 4Q25, which further increases pressure from a financing overhang, the analyst tells investors in a research note. Based on new data from the interim update from the single dose and early look at the open-label extension, the firm continues to have confidence in our view that briquilimab can be differentiated on a dosing schedule and risk/benefit profile.

H.C. Wainwright

Buy

downgrade

$40 -> $20

2025-07-07

Reason

H.C. Wainwright

Price Target

$40 -> $20

2025-07-07

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on Jasper Therapeutics to $20 from $40 and keeps a Buy rating on the shares after the company's "surprising update" that the 240 mg every 8 week and 240 mg loading dose plus 180 mg every 8 week cohorts in the BEACON trial evaluating briquilimab for treatment of chronic spontaneous urticaria were impacted by issues with one drug product lot. The firm updated its model to shift its launch estimates for CSU and chronic inducible urticaria in the U.S. to 2030 and 2031, respectively, and to account for the company's cost-cutting plans and lower operating expenses in 2025. However, the firm still believes the company will need to raise capital and currently estimates a $5M raise.

William Blair

Outperform -> Market Perform

downgrade

2025-07-07

Reason

William Blair

Price Target

2025-07-07

downgrade

Outperform -> Market Perform

Reason

William Blair downgraded Jasper Therapeutics to Market Perform from Outperform after the company reported updated data from the BEACON study and preliminary data from the open-label extension of briquilimab in chronic spontaneous urticaria. Jasper also disclosed that some of the multi-dose cohorts from BEACON were impacted by an inactive drug product lot and that development of briquilimab in asthma has been halted because the same inactive drug product lot was used for all patients in the ETESIAN asthma challenge study, the analyst noted. The firm is downgrading shares as a result of this \"setback,\" citing a lack of clarity around both the funding overhang and concerns related to drug product manufacturing.

Valuation Metrics

The current forward P/E ratio for Jasper Therapeutics Inc (JSPR.O) is -0.62, compared to its 5-year average forward P/E of -3.72. For a more detailed relative valuation and DCF analysis to assess Jasper Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-3.72

Current PE

-0.62

Overvalued PE

-0.47

Undervalued PE

-6.97

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.55

Current EV/EBITDA

-0.02

Overvalued EV/EBITDA

1.68

Undervalued EV/EBITDA

-4.77

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.56

Current PS

0.00

Overvalued PS

3.55

Undervalued PS

-2.42

Financials

Annual

Quarterly

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 364.54% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

JSPR News & Events

Events Timeline

No data

News

5.0

01-07Globenewswire

Jasper Appoints Jeet Mahal as CEO, Focuses on Chronic Urticaria Treatment

9.0

2025-12-02Benzinga

Jasper Stock Soars Following Positive Results from New Asthma Study

9.0

2025-12-02Globenewswire

Jasper Reports Positive ETESIAN Study Data for Briquilimab, 180mg Dose Shows Significant Asthma Improvement

People Also Watch

Frequently Asked Questions

What is Jasper Therapeutics Inc (JSPR) stock price today?

The current price of JSPR is 1.51 USD — it has decreased -9.04 % in the last trading day.

What is Jasper Therapeutics Inc (JSPR)'s business?

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics targeting mast cell-driven diseases, such as Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CIndU), and Asthma. The Company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (c-Kit) receptor on mast and stem cells. Briquilimab is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the cell-surface receptor c-Kit, also known as CD117, thereby inhibiting signaling through the receptor. The SCF/c-Kit pathway is a survival signal for mast cells. It is also developing briquilimab as a one-time conditioning therapy for severe combined immunodeficiency (SCID) patients undergoing a second stem cell transplant for which it is conducting a Phase 1/2 clinical trial.

What is the price predicton of JSPR Stock?

What is Jasper Therapeutics Inc (JSPR)'s revenue for the last quarter?

Jasper Therapeutics Inc revenue for the last quarter amounts to -19.17M USD, decreased -3.64 % YoY.

What is Jasper Therapeutics Inc (JSPR)'s earnings per share (EPS) for the last quarter?

Jasper Therapeutics Inc. EPS for the last quarter amounts to -16999000.00 USD, increased 18.66 % YoY.

What changes have occurred in the market's expectations for Jasper Therapeutics Inc (JSPR)'s fundamentals?

How many employees does Jasper Therapeutics Inc (JSPR). have?

Jasper Therapeutics Inc (JSPR) has 64 emplpoyees as of January 10 2026.

What is Jasper Therapeutics Inc (JSPR) market cap?

Today JSPR has the market capitalization of 42.26M USD.